Serum Procalcitonin Level May Predict Acute Kidney Injury in ICU Patients With Sepsis

March 25, 2017 updated by: Mahmoud Hamada imam, Benha University
The aim of this study is to examine if procalcitonin (PCT) can be used for early prediction of AKI septic patients in ICU.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

67 patients with sepsis were enrolled in this study. On admission, PCT was measured together with serum creatinine, urea, and other inflammatory markers. Quick Sepsis-related Organ Failure Assessment was calculated at the emergency department. Patients were classified into those with Acute kidney injury (AKI) and non-AKI groups.

Study Type

Observational

Enrollment (Actual)

67

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

ICU patients with sepsis

Description

Inclusion Criteria:

  • ICU patients with sepsis

Exclusion Criteria:

  • Patient known to have End-stage kidney disease
  • Patients on Renal replacement therapy
  • patients without procalcitonin level within 24 hours from admission.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
AKI GROUP
measure Procalcitonin among Patient developed Acute kidney injury during ICU stay
Diagnostic test: measure Serum procalcitonin level
measuring procalcitonin level
Non-AKI group
measure Procalcitonin among Patient did not develop Acute kidney injury during ICU stay
Diagnostic test: measure Serum procalcitonin level
measuring procalcitonin level

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
development of AKI
Time Frame: 28 Days
elevated kidney functions creatinine or oliguria
28 Days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Benha University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2014

Primary Completion (Actual)

February 28, 2017

Study Completion (Actual)

March 1, 2017

Study Registration Dates

First Submitted

March 25, 2017

First Submitted That Met QC Criteria

March 25, 2017

First Posted (Actual)

March 31, 2017

Study Record Updates

Last Update Posted (Actual)

March 31, 2017

Last Update Submitted That Met QC Criteria

March 25, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Benha317

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Kidney Injury

Clinical Trials on measure Serum procalcitonin level

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe